ArticleAlzheimer's research & therapy2026
Alzheimer's disease and cerebrovascular biomarkers in relation to odor identification in a naturalistic clinical cohort.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlfactory deficits, especially in odor identification (OID), have been linked to Alzheimer's disease (AD), likely due to regional proteinopathy and atrophy in the olfactory brain circuit. Their cognitive and biological correlates across the clinical spectrum, particularly in individuals with no evident cognitive impairment, have been underexplored. This examination is relevant because many individuals of this group will not progress to dementia, and olfactory deficits may reflect ongoing pathological processes and could enrich risk stratification.
methodsWe analyzed data from a cohort of 233 subjective cognitive impairment (SCI, n=152), mild cognitive impairment (MCI, n=50), and AD dementia (n=31) individuals from the Karolinska University Hospital Memory Clinic (Solna, Sweden). We examined the association of performance on the 16-item Sniffin' Sticks OID test (free and total [free or cued] identification scores) with a range of markers: cognitive performance, cerebrospinal fluid biomarkers, AD- and olfactory-related brain volumes, and white matter hyperintensities volume. We performed correlation analyses, generalized additive models, and threshold regressions, adjusted for sociodemographic factors and APOE status.
resultsOID performance was better in SCI compared to MCI and AD. Aβ42/40 ratio was positively associated with OID in SCI and AD, with APOE ε4 carriers driving this association in SCI. Hippocampal volume was positively associated with OID in AD. Higher volume of white matter hyperintensities was negatively associated with OID in MCI. The relationships of OID with Aβ42/40 and hippocampal volume were linear in the whole cohort. Worse verbal episodic memory performance was associated with lower OID scores only in the AD group. Free OID showed a broader and stronger pattern of associations with episodic memory and biomarkers compared with total OID. Threshold regression between free OID and Aβ42/40 identified a subthreshold value (<0.94) above the clinical cutoff (<0.86), capturing nine non-demented individuals within the gray zone between these cutoffs.
conclusionsOur findings support an association between amyloid levels and olfactory performance in the AD spectrum, underscoring the potential of smell tests as cost-effective tools in multimodal stratification frameworks. In dementia stages, medial temporal atrophy accompanied by memory impairment may be the main correlate of olfactory deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.